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Abstract
Introduction: Although active gonadotropin-secreting pituitary adenomas are considered very rare, the vast majority of pituitary tumours 
diagnosed as “non-functioning” express gonadotropins or their free β or α subunits. However, systemic investigations comparing the 
serum concentrations of follitropin (FSH), lutropin (LH), and α–subunit (αSU) before surgery with the immunoreactivity of the respective 
substances in the excised tumours are still lacking. 
Material and methods: Immunostaining of FSH, LH, and αSU was compared in 43 surgically removed gonadotropin — expressing pitu-
itary adenomas with serum concentrations of the above-mentioned substances before surgery in the same patients. 
Results: The serum concentrations of FSH were elevated (> 11.6 mU/mL) in 8/12 (66.7%) cases of FSH-positive adenomas. By contrast, 
in FSH–negative tumours the elevation of FSH is absent. Moreover, only 1/25 (4%) patients with LH–positive adenoma had the elevated 
serum concentration of LH (51.5 mU/mL). The overproduction of LH was not observed in adenomas expressing free β LH or in LH-negative 
tumours. In patients with αSU-positive adenomas elevated serum levels of αSU were observed in 3/15 (20%) cases. No αSU elevations were 
observed in patients with αSU–negative adenomas. The mean serum FSH, LH, and αSU concentrations were higher in patients with FSH, 
LH, and/or αSU immunopositive tumours in comparison with immunonegative. However, the differences are not statistically significant. 
Conclusions: Although “silent” gonadotropinomas constitute a frequent subtype of pituitary adenomas, the “active” subtype (i.e. manifesting 
by gonadotropin excess) are rare (approx. 4% of all pituitary adenomas). Gonadotropinomas are difficult to diagnose before surgery. The 
measurement of gonadotropins including αSU is needed but often not sufficient for presurgical diagnosis. (Endokrynol Pol 2018; 69 (5): 526–529)
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Streszczenie
Wstęp: Jakkolwiek „aktywne” gruczolaki przysadki wydzielające gonadotropiny uważane są za bardzo rzadkie to większość guzów przy-
sadki rozpoznawanych jako „nieczynne wydzielniczo” w rzeczywistości wykazuje ekspresję gonadotropin lub ich wolnych podjednostek 
β lub α. Brak jednak dotąd systematycznych badań, które porównywałyby przedoperacyjne stężenia folitropiny (FSH), lutropiny (LH) 
i ich podjednostki α (αSU) w surowicy krwi z immunoreaktywnością usuniętych operacyjnie guzów.
Materiał i metody: W usuniętych operacyjnie 43 gruczolakach gonadotropowych przysadki, porównano odczyny immunohistochemiczne 
na FSH, LH i αSU ze stężeniami tych hormonów oznaczonymi we krwi pacjentów przed operacją.
Wyniki: Podwyższone stężenie FSH we krwi (> 11,6 mU/mL) stwierdzono u 8/12 (66,7%) pacjentów z dodatnim odczynem na FSH 
w guzie. W grupie chorych z gruczolakami ujemnymi dla FSH nie obserwowano podwyższonego stężenia FSH w surowicy w żadnym 
przypadku. W przypadku gruczolaków LH-pozytywnych, podwyższenie LH we krwi stwierdzono tylko w 1 przypadku na 25 (4%) 
(51,5 mU/mL). Podwyższonego stężenia LH nie obserwowano także w przypadkach gruczolaków z ekspresją wolnej podjednostki β-LH 
oraz LH-negatywnych. W przypadkach gruczolaków αSU-pozytywnych podwyższone stężenia αSU w surowicy krwi (> 1 mU/mL), 
stwierdzono w 3 przypadkach na 15 (20%), natomiast w guzach αSU-negatywnych podwyższonych stężeń nie obserwowano w żadnym 
przypadku. Średnie stężenia FSH, LH i a αSU w surowicy krwi były wyższe u pacjentów z guzami odpowiednio FSH, LH i αSU pozytyw-
nymi w porównaniu z pacjentami z guzami immunonegatywnymi dla tych hormonów; różnice nie były jednak statystycznie znamienne.
Wnioski: Jakkolwiek „ciche” gonadotropinoma stanowią częsty podtyp gruczolaków przysadki, to „aktywne” (tj. manifestujące się nad-
miarem gonadotropin) gonadotropinoma są rzadkością (ok. 4% wszystkich gruczolaków przysadki). Gruczolaki gonadotropowe są trudne 
do zdiagnozowania przed operacją. Oznaczenie gonadotropin oraz αSU są konieczne, lecz najczęściej niewystarczające do rozpoznania 
przedoperacyjnego. (Endokrynol Pol 2018; 69 (5): 526–529)
Słowa kluczowe: gonadotropinoma, folitropina, lutropina, α-podjednostka 
Prof. Marek Pawlikowski, MD, PhD, Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz,  
ul. Pomorska 251, 92–213 Łódź; e-mail: marek.pawlikowski@umed.lodz.pl
527
Endokrynologia Polska 2018; 69 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
numerical data were analysed using the programme 
Statistica 12. 
The study was approved by the Ethical Committee 
of the Medical University of Lodz, decision RNN/351/17/
KE dated November 21st, 2017.
Results
All tumours were diagnosed before surgery as non-
functioning pituitary adenomas. In one case concerning 
a 54-year-old woman with extremely high FSH and LH 
elevation a suggestion of gonadotropinoma diagnosis 
was included into anamnesis.
As shown in ‘Materials and Methods’, the gonad-
otropin-expressing pituitary adenomas affect mainly 
middle-aged and older patients. There is some ten-
dency towards younger mean age in the males, but 
the difference with female patients is not statistically 
significant. The frequency of gonadotropin-expressing 
adenomas in both sexes is similar. In 36 adenomas the 
immunopositivity concerned LH and in 13 adenomas 
the immunopositivity concerned FSH. In six adeno-
mas both gonadotropins were present. Moreover, in 
11 cases of LH-immunopositive and in one case of 
FSH-immunopositive tumour, the immunoreaction 
for αSU was lacking. We concluded that those ad-
enomas presented the expression of free β subunits. 
In patients with LH-positive adenomas only one 
(a 54-year-old woman) had elevated LH in blood serum 
(51.5 mU/ml). The remaining patients with LH-positive 
tumours presented normal or even decreased serum 
LH concentrations (Table I), in spite of the fact that 
this group included 12 women of menopausal or post-
menopausal age. The mean value of LH concentrations 
in patients with LH-positive tumours is slightly higher 
than in free β-LH subunit expressing or in LH-negative 
adenomas, but the differences between the means are 
not statistically significant. In 12 patients exhibiting 
FSH immunopositivity of adenoma, in the majority of 
cases (seven women and one man) serum FSH concen-
trations were elevated. All these women were in the 
postmenopausal age (> 50 years). In the remaining four 
cases of FSH-positive tumours, serum concentration 
of FSH was normal or decreased (Table II). Excluding 
one case of a 72-year-old woman, the three remain-
ing cases concerned men. In one case we suspect the 
expression of free β-FSH subunit because of the lack of 
αSU immunostaining. In patients with FSH-negative 
tumours no elevation of serum FSH was observed. In 
the remaining 30 patients serum FSH concentrations 
were situated within normal limits, and in five cases 
they were decreased. Eleven cases concerned women, 
and all of them in menopausal or post-menopausal age. 
The mean value of FSH concentrations in patients with 
Introduction 
Initially, gonadotropin expressing tumours (gonado-
tropinomas) were considered as a very rare subtype 
of pituitary adenoma. The specific clinical symptoms 
of these tumours were rarely observed. Precocious 
puberty in young boys, ovarian overstimulation in 
young women, and testicular enlargement in adult 
men were occasionally reported [1–3]. In the aged 
people no specific clinical symptoms of gonadotropi-
noma were observed, and those tumours are classi-
fied as non-functioning pituitary adenomas (NFPA). 
However, when immunohistochemical investigation 
with antibodies against pituitary hormones became 
a routine and obligatory procedure of pathomorpho-
logical examination of excised pituitary tumours, it 
was found that the vast majority of NFPA express 
gonadotropins or their subunits [4–8]. Moreover, it 
was recently shown, on the basis of molecular and in 
vitro studies, that even the adenomas totally immuno-
negative for pituitary hormones (null cell adenomas — 
NCA) express gonadotropins [9]. However, according 
to our knowledge, the systematic studies comparing 
the presurgical serum concentrations of follitropin 
(FSH), lutropin (LH), and α-subunit (αSU) with im-
munoreactivity of the above-mentioned hormones in 
post-surgical samples are still lacking.
Material and methods
Archival material of 165 immunohistochemically exa-
mined pituitary adenomas was included in the study. 
FSH and LH were detected using anti-FSH and anti-LH 
monoclonal antibodies (DAKO Denmark or Chemicon 
MERCK) and αSU with anti-αSU monoclonal antibody 
(Immunotech France). The visualisation of immunos-
taining was performed using an Envision kit (DAKO 
Denmark) with the use of 3,3’ diaminobenzidine (DAB) 
as chromogen. 
In 78 tumours positive immunostaining for FSH, 
LH, and/or their free β-subunits was found; in 43 
cases (21 women and 22 men) clinical documentation, 
including the results of gonadotropin measurement in 
blood serum before surgery, was available. FSH and 
LH were measured by means of chemiluminescence 
method (OCD Johnson & Johnson, UK). Additionally, 
in 21 cases (9 women and 12 men) αSU concentration 
was examined using IRMA (Immunotech, France) 
method. The female patients were aged 41–73 years 
(mean age 60.0 ± 9 years), and males were aged 39–77 
years (mean age 55.8 ± 11 years). In the patients the 
confrontation of the results of the immunohistochemi-
cal study and of FSH, LH, and αSU measurements 
in peripheral blood serum was performed. The 
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FSH-positive tumours is over twofold higher than in 
those with FSH-negative adenomas. However, the dif-
ference is not statistically significant because of a high 
dispersion of the results. In 21 cases, in addition to FSH 
and LH, the αSU concentration was measured (Table III). 
The elevated αSU concentration was observed in 3/15 
cases (20%) of αSU-positive tumours. In contrast, in 
anyone of the patients with αSU-negative adenomas an 
elevated αSU concentration was observed. The mean 
values of αSU concentrations in αSU-positive adenomas 
were higher than in cases of α-SU-negative adenomas, 
but the difference is not statistically significant.
Discussion
The data presented above support the view that while 
hormonally active gonadotropinomas are rare, the 
vast majority of non-functioning pituitary tumours 
(NFPA) express gonadotropins [4–8]. Our findings 
confirm the statement that FSH hypersecretion is 
more frequent than that of LH [10]. However, the 
positive immunostaining for LH, and specifically for 
the free β-LH subunit, is more frequent in comparison 
with FSH. Since the frequency of NFPA constitutes 
approximatively 30% of all pituitary tumours [6, 7, 10], 
it means that gonadotropinomas can be estimated 
for about 20% of all pituitary adenomas. This value is 
compatible with earlier published data (24% accord-
ing to [10]). A question that remains to be answered 
is the proportion of “active (over-secreting)” versus 
the “silent” gonadotropinomas (i.e. the gonadotropi-
nomas not manifesting themselves by enhanced go-
nadotropin levels). The answer is not simple because 
reliable determination of whether the elevated FSH 
is of tumoural origin or generated by the remaining 
non-tumoural pituitary is not possible. However, the 
women with FSH-negative tumours, in spite of the 
postmenopausal age, did not present, in any case, 
elevation of serum FSH. This finding speaks in favour 
of tumoural origin of elevated FSH in patients with 
FSH-positive adenomas. If we consider all nine of the 
cases of gonadotropin over-secretion observed in our 
study, the frequency of “active” gonadotropinomas 
could be estimated for approximately 21% of the 
all gonadotropin-expressing tumours, and for 4.2% 
of the pituitary adenomas in general. As expected, 
the vast majority of gonadotropinomas (mostly ex-
pressing LH or free β-LH) are “silent”. The causes 
of this phenomenon are not known, but it could be 
hypothesised that they may result — at least in part 
— from the absence of the α-subunit or the lack of 
the mutual junction between α and β subunits. This 
Table II. Serum FSH concentrations in patients with pituitary 
adenomas
Tabela II. Stężenia FSH w surowicy chorych z gruczolakami 
przysadki
Patients/Tumours Serum FSH 
concentrations  
in patients  
with FSH-positive  
pituitary adenomas
Serum FSH 
concentrations  
in patients  
with FSH-negative 
pituitary adenomas
Total number 12 (100%) 35 (100%)
Elevated* 8 (66.7%) 0 (0%) 
Normal* 3 (25%) 30 (85.7%)
Decreased* 1 (8.3%) 5 (14.3%)
Mean ± SEM 20.6 ± 12.1  
mU/mL
7.6 ± 1.74  
mU/mL
*Reference ranges [1.38–11.6 mU/mL]
Table I. Serum LH concentrations in patients with pituitary 
adenomas 
Tabela I. Stężenia LH w surowicy chorych z gruczolakami 
przysadki
Patients/
Tumours
Serum LH 
concentrations 
in patients with 
LH-positive 
pituitary 
adenomas
Serum LH 
concentrations 
in patients with 
free β LH-
positive pituitary 
adenomas
Serum LH 
concentrations 
in patients with 
LH-negative 
pituitary 
adenomas
Total number 25 (100%) 11 (100%) 10 (100%)
Elevated* 1 (4%) 0 (0%) 0 (0%)
Normal* 15 (60%) 6 (54.5%) 9 (90%)
Decreased* 9 (36%) 5 (45.5%) 1 (10%)
Mean ± 
SEM
3.1 ± 0.74  
mU/mL
1.7 ± 0.72  
mU/mL
3.4 ± 1.1  
mU/mL
*reference ranges [0.83–15.5 mU/mL]
Table III. Serum αSU concentrations in patients with 
pituitary adenomas
Tabela III. Stężenia αSU w surowicy chorych z gruczolakami 
przysadki
Patients/
Tumours
Serum αSU 
concentrations  
in patients  
with αSU-positive  
pituitary  
adenomas
Serum αSU 
concentrations  
in patients  
with αSU-negative 
pituitary  
adenomas
Total  
number
15 (100%) 6 (100%)
Elevated* 3 (20%) 0 (0%)
Normal* 12 (80%) 6 (100%)
Mean ±  
SEM
1.9 ± 0.9  
mU/mL
0.33 ± 0.02  
mU/mL
*reference ranges [0–1.0 mU/mL]
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is supported not only by the frequent expression of 
free β-LH, but also by the disproportion of LH, FSH, 
and αSU immunostained cells often observed in these 
adenomas. This presumption is also supported by the 
observation of the presence of the frequent detection 
of free subunits: mainly β-LH subunit, more rarely 
free β-FSH [11]. The possibilities of correct presur-
gical diagnosis of gonadotropinoma, especially in 
middle-aged and elderly people, remain limited. The 
determination of FSH, LH, and αSU in blood before 
surgery should be obligatory, but is usually insuf-
ficient because very low or even undetectable levels 
of these substances do not exclude the diagnosis of 
gonadotropinoma. According to some recent pub-
lications, presurgical diagnosis might be improved 
by the measurement of αSU after thyroliberin (TRH) 
administration [12, 13].
However, the sensitivity of this test may be limited 
because of the absence of αSU in many tumours. 
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